参考文献/References:
[1] 陈万青, 郑荣寿, 曾红梅, 等.2011年中国恶性肿瘤发病和死亡分析[J].中国肿瘤, 2015, 24(1):1-10.DOI:10.11735/j.issn.1004-0242.2015.01.A001.Chen WQ, Zheng RS, Zeng HM, et al.Report of cancer incidence and mortality in China, 2011[J].China Cancer, 2015, 24(1):1-10.
[2] Cataldo VD, Gibbons DL, Pérez-Soler R, et al.Treatment of non-small-cell lung cancer with erlotinib or gefitinib[J].N Engl J Med, 2011, 364(10):947-955.DOI:10.1056/NEJMct0807960.
[3] Mendelsohn J, Baselga J.Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer[J].J Clin Oncol, 2003, 21(14):2787-2799.DOI:10.1200/JCO.2003.01.504.
[4] Rudin M, Weissleder R.Molecular imaging in drug discovery and development[J].Nat Rev Drug Discov, 2003, 2(2):123-131.DOI:10.1038/nrd1007.
[5] Green MR.Targeting targeted therapy[J].N Engl J Med, 2004, 350(21):2191-2193.DOI:10.1056/NEJMe048101.
[6] Gridelli C, Marinis F, Maio M, et al.Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation:Review of the evidence[J].Lung Cancer, 2011, 71(3):249-257.DOI:10.1016/j.lungcan.2010.12.008.
[7] Jian G, Songwen Z, Ling Z, et al.Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer[J].J Cancer Res Clin Oncol, 2010, 136(9):1341-1347.DOI:10.1007/s00432-010-0785-z.
[8] Bai H, Mao L, Wang HS, et al.Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer[J].J Clin Oncol, 2009, 27(16):2653-2659.DOI:10.1200/JCO.2008.17.3930.
[9] Johnström P, Fredriksson A, Thorell JO, et al.Synthesis of[methoxy-11C]PD153035, a selective EGF receptor tyrosine kinase inhibitor[J].J Labelled Comp Radiopharm, 1998, 41(7):623-629.DOI:10.1002/(SICI)1099-1344(199807)41:73.0.CO;2-Q.
[10] Fredriksson A, Johnström P, Thorell JO, et al.In vivo evaluation of the biodistribution of 11C-labeled PD153035 in rats without and with neuroblastoma implants[J].Life Sci, 1999, 65(2):165-174.DOI:10.1016/S0024-3205(99)00233-7.
[11] Samén E, Thorell JO, Fredriksson A, et al.The tyrosine kinase inhibitor PD153035:implication of labeling position on radiometabolites formed in vitro[J].Nucl Med Biol, 2006, 33(8):1005-1011.DOI:10.1016/j.nucmedbio.2006.09.008.
[12] Samén E, Arnberg F, Lu L, et al.Metabolism of epidermal growth factor receptor targeting probe[11C]PD153035:impact on biodistribution and tumor uptake in rats[J].J Nucl Med, 2013, 54(10):1804-1811.DOI:10.2967/jnumed.113.120493.
[13] Wang H, Yu JM, Yang GR, et al.Further characterization of the epidermal growth factor receptor ligand 11C-PD153035[J].Chin Med J(Engl), 2007, 120(11):960-964.
[14] Wang H, Yu J, Yang G, et al.Assessment of 11C-labeled-4-N-(3-bromoanilino)-6, 7-dimethoxyquinazoline as a positron emission tomography agent to monitor epidermal growth factor receptor expression[J].Cancer Sci, 2007, 98(9):1413-1416.DOI:10.1111/j.1349-7006.2007.00562.x.
[15] Liu N, Li M, Li X, et al.PET-based biodistribution and radiation dosimetry of epidermal growth factor receptor-selective tracer 11C-PD153035 in humans[J].J Nucl Med, 2009, 50(2):303-308.DOI:10.2967/jnumed.108.056556.
[16] Meng X, Loo BW Jr, Ma L, et al.Molecular imaging with 11C-PD153035 PET/CT predicts survival in non-small cell lung cancer treated with EGFR-TKI:a pilot study[J].J Nucl Med, 2011, 52(10):1573-1579.DOI:10.2967/jnumed.111.092874.
[17] DeJesus OT, Murali D, Flores LG, et al.Synthesis of[F-18]-ZD1839 as a PET imaging agent for epidermal growth factor receptors[J].J Labelled Comp Radiopharm, 2003, 46(S1):S1-S9.DOI:10.1002/jlcr.750.
[18] Murali D, Flores LG, Converse AK, et al.Evaluation of[F-18] Iressa as a PET agent for tumor overexpressing epidermal growth factor (EGFR) receptors[J].J Labelled Comp Radiopharm, 2005, 48(s1):1-11.DOI:10.1002/jlcr.968.
[19] Seimbille Y, Phelps ME, Czernin J, et al.Fluorin-18 labeling of 6, 7-distributed anilinoquinazoline derivatives for positron emission tomography(PET) imaging of tyrosine kianse receptors:synthesis of 18F-Iressa and related molecular probes[J].J Labelled Comp Radiopharm, 2005, 48(11):829-843.DOI:10.1002/jlcr.998.
[20] Su H, Seimbille Y, Ferl GZ, et al.Evaluation of[18F] gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors[J].Eur J Nucl Med Mol Imaging, 2008, 35(6):1089-1099.DOI:10.1007/s00259-007-0636-6.
[21] Läppchen T, Vlaming ML, Custers E, et al.Automated synthesis of[18F] gefitinib on a modular system[J].Appl Radiat Isot, 2012, 70(1):205-209.DOI:10.1016/j.apradiso.2011.09.005.
[22] Holt DP, Ravert HT, Dannals RF, et al.Synthesis of[11C] gefitinib for imaging epidermal growth factor receptor tyrosine kinase with positron emission tomography[J].J Labelled Comp Radiopharm, 2006, 49(10):883-888.DOI:10.1002/jlcr.1104.
[23] Wang JQ, Gao M, Miller KD, et al.Synthesis of[11C] Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase[J].Bioorg Med Chem Lett, 2006, 16(15):4102-4106.DOI:10.1016/j.bmcl.2006.04.080.
[24] Zhang MR, Kumata K, Hatori A, et al.[11C]Gefitinib([11C] Iressa):radiosynthesis, in vitro uptake, and in vivo imaging of intact murine fibrosarcoma[J].Mol Imaging Biol, 2010, 12(2):181-191.DOI:10.1007/s11307-009-0265-5.
[25] Kawamura K, Yamasaki T, Yui J, et al.In vivo evaluation of P-glycoprotein and breast cancer resistance protein modulation in the brain using[11C] gefitinib[J].Nucl Med Biol, 2009, 36(3):239-246.DOI:10.1016/j.nucmedbio.2008.12.006.
[26] Vlaming ML, Läppchen T, Jansen HT, et al.PET-CT imaging with[18F]-gefitinib to measure Abcb1a/1b(P-gp)and Abcg2(Bcrp1)mediated drug-drug interactions at the murine blood-brain barrier[J].Nucl Med Biol, 2015, 42(11):833-841.DOI:10.1016/j.nucmedbio.2015.07.004.
[27] Memon AA, Jakobsen S, Dagnaes-Hansen F, et al.Positron emission tomography(PET) imaging with[11C]-labeled erlotinib:a micro-PET study on mice with lung tumor xenografts[J].Cancer Res, 2009, 69(3):873-878.DOI:10.1158/0008-5472.CAN-08-3118.
[28] Memon AA, Weber B, Winterdahl M, et al.PET imaging of patients with non-small cell lung cancer employing an EGF receptor targeting drug as tracer[J].Br J Cancer, 2011, 105(12):1850-1855.DOI:10.1038/bjc.2011.493.
[29] Weber B, Winterdahl M, Memon A, et al.Erlotinib accumulation in brain metastases from non-small cell lung cancer:visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor[J].J Thorac Oncol, 2011, 6(7):1287-1289.DOI:10.1097/JTO.0b013e318219ab87.
[30] Petrulli JR, Sullivan JM, Zheng MQ, et al.Quantitative analysis of[11C]-erlotinib PET demonstrates specific binding for activating mutations of the EGFR kinase domain[J].Neoplasia, 2013, 15(12):1347-1353.DOI:10.1593/neo.131666.
[31] Abourbeh G, Itamar B, Salnikov O, et al.Identifying erlotinib-sensitive non-small cell lung carcinoma tumors in mice using[11C]erlotinib PET[J/OL].EJNMMI Res, 2015, 5:4[2016-08-16].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4385014.DOI:10.1186/s13550-014-0080-0.
[32] Traxl A, Wanek T, Mairinger S, et al.Breast Cancer Resistance Protein and P-Glycoprotein Influence in Vivo Disposition of 11C-Erlotinib[J].J Nucl Med, 2015, 56(12):1930-1936.DOI:10.2967/jnumed.115.161273.
[33] Bahce I, Smit EF, Lubberink M, et al.Development of[11C]erlotinib positron emission tomography for in vivo evaluation of EGF receptor mutational status[J].Clin Cancer Res, 2013, 19(1):183-193.DOI:10.1158/1078-0432.CCR-12-0289.
[34] Yaqub M, Bahce I, Voorhoeve C, et al.Quantitative and simplified analysis of 11C-Erlotinib studies[J].J Nucl Med, 2016, 57(6):861-866.DOI:10.2967/jnumed.115.165225.
[35] Bahce I, Yaqub M, Errami H, et al.Effects of erlotinib therapy on[11C]erlotinib uptake in EGFR mutated, advanced NSCLC[J/OL].EJNMMI Res, 2016, 6(1):10[2016-08-16].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4746207.DOI:10.1186/s13550-016-0169-8.
[36] 黄顺, 王全师, 郑希, 等.一种EGFR正电子示踪剂及其制备方法和应用:中国, 201510114513.X[P].2015-08-05.Huang S, Wang QS, Zhen X, et al.The preparation and application of an EGFR positron tracer:CN, 201510114513.X[P].2015-08-05.
[37] Basuli F, Wu H, Li C, et al.A first synthesis of 18F-radiolabeled lapatinib:a potential tracer for positron emission tomographic imaging of Erbb1/Erbb2 tyrosine kinase activity[J].J Labelled Comp Radiopharm, 2011, 54(9):633-636.DOI:10.1002/jlcr.1898.
[38] Saleem A, Searle GE, Kenny LM, et al.Lapatinib access into normal brain and brain metastases in patients with HER-2 overexpressing breast cancer[J/OL].EJNMMI Res, 2015, 5:30[2016-08-16].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4424224.DOI:10.1186/s13550-015-0103-5.
[39] Gao M, Lola CM, Wang M, et al.Radiosynthesis of[11C]Vandetanib and[11C]chloro-Vandetanib as new potential PET agents for imaging of VEGFR in cancer[J].Bioorg Med Chem Lett, 2011, 21(11):3222-3226.DOI:10.1016/j.bmcl.2011.04.049.
[40] Li F, Jiang S, Zu Y, et al.A tyrosine kinase inhibitor-based high-affinity PET radiopharmaceutical targets vascular endothelial growth factor receptor[J].J Nucl Med, 2014, 55(1):1525-1531.DOI:10.2967/jnumed.114.138925.
[41] Samén, E, Li L, Mulder J, et al.Visualization of angiogenesis during cancer development in the polyoma middle T breast cancer model:molecular imaging with(R)-[11C]PAQ[J/OL].EJNMMI Res, 2014, 4(1):17[2016-08-16].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3986910.DOI:10.1186/2191-219X-4-17.
[42] Murakami H, Tamura T, Takahashi T, et al.Phase I study of continuous afatinib(BIBW 2992) in patients with advanced non-small cell lung cancer afterprior chemotherapy/erlotinib/gefitinib (LUX-Lung 4)[J].Cancer Chemother Pharmacol, 2012, 69(4):891-899.DOI:10.1007/s00280-011-1738-1.
[43] Slobbe P, Windhorst AD, Stigter-van Walsum M, et al.Development of[18F] afatinib as new TKI-PET tracer for EGFR positive tumors[J].Nucl Med Biol, 2014, 41(9):749-757.DOI:10.1016/j.nucmedbio.2014.06.005.
[44] Slobbe P, Windhorst AD, Stigter-van Walsum M, et al.A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors[11C]erlotinib and[18F]afatinib in lung cancer-bearing mice[J/OL].EJNMMI Res, 2015, 5(1):14[2016-08-16].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4385286.DOI:10.1186/s13550-015-0088-0.
[45] Pal A, Glekas A, Doubrovin M, et al.Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography[J].Mol Imaging Biol, 2006, 8(5):262-277.DOI:10.1007/s11307-006-0049-0.
[46] Tian M, Ogawa K, Wendt R, et al.Whole-body biodistribution kinetics, metabolism, and radiation dosimetry estimates of 18F-PEG6-IPQA in nonhuman primates[J].J Nucl Med, 2011, 52(6):934-941.DOI:10.2967/jnumed.110.086777.
[47] Yeh HH, Ogawa K, Balatoni J, et al.Molecular imaging of active mutant L858R EGF receptor(EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT[J].Proc Natl Acad Sci U S A, 2011, 108(4):1603-1608.DOI:10.1073/pnas.1010744108.
[48] Pal A, Balatoni JA, Mukhopadhyay U, et al.Radiosynthesis and initial in vitro evaluation of[18F]F-PEG6-IPQA-a novel PET radiotracer for imaging EGFR expression-activity in lung carcinomas[J].Mol Imaging Biol, 2011, 13(5):853-861.DOI:10.1007/s11307-010-0408-8.
[49] Medina OP, Pillarsetty N, Glekas A, et al.Optimizing tumor targeting of the lipophilic EGFR-binding radiotracer SKI 243 using a liposomal nanoparticle delivery system[J].J Control Release, 2011, 149(3):292-298.DOI:10.1016/j.jconrel.2010.10.024.
[50] Yeh SH, Lin CF, Kong FL, et al.Molecular imaging of nonsmall cell lung carcinomas expressing active mutant EGFR kinase using PET with[124I]-morpholino-IPQA[J/OL].Biomed Res Int, 2013, 2013:549359[2016-08-16].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3730369.DOI:10.1155/2013/549359.
[51] Bonasera TA, Ortu G, Rozen Y, et al.Potential 18F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase[J].Nucl Med Biol, 2001, 28(4):359-374.DOI:10.1016/S0969-8051(01)00200-1.
[52] Ortu G, Ben-David I, Rozen Y, et al.Labeled EGFr-TK irreversible inhibitor(ML03):in vitro and in vivo properties, potential as PET biomarker for cancer and feasibility as anticancer drug[J].Int J Cancer, 2002, 101(4):360-370.DOI:10.1002/ijc.10619.
[53] Ben-David I, Rozen Y, Ortu G, et al.Radiosynthesis of ML03, a novel positron emission tomography biomarker for targeting epidermal growth factor receptor via the labeling synthon:[11C]acryloyl chloride[J].Appl Radiat Isot, 2003, 58(2):209-217.DOI:10.1016/S0969-8043(02)00301-9.
[54] Mishani E, Abourbeh G, Rozen Y, et al.Novel carbon-11 labeled 4-dimethylamino-but-2-enoic acid[4-(phenylamino)-quinazoline-6-yl]-amides:potential PET bioprobes for molecular imaging of EGFR-positive tumors[J].Nucl Med Biol, 2004, 31(4):469-476.DOI:10.1016/j.nucmedbio.2003.12.005.
[55] Dissoki S, Laky D, Mishani E.Fluorine-18 labeling of ML04-presently the most promising irreversible inhibitor candidate for visualization of EGFR in cancer[J].J Label Compd Radiopharm, 2006, 49(6):533-543.DOI:10.1002/jlcr.1071.
[56] Abourbeh G, Dissoki S, Jacobson O, et al.Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors[J].Nucl Med Biol, 2007, 34(1):55-70.DOI:10.1016/j.nucmedbio.2006.10.012.
[57] Shaul M, Abourbeh G, Jacobson O, et al.Novel iodine-124 labeled EGFR inhibitors as potential PET agents for molecular imaging in cancer[J].Bioorg Med Chem, 2004, 12(13):3421-3429.DOI:10.1016/j.bmc.2004.04.044.
[58] Dissoki S, Aviv Y, Laky D, et al.The effect of the[18F]-PEG group on tracer qualification of[4-(phenylamino)-quinazoline-6-YL]-amide moiety-an EGFR putative irreversible inhibitor[J].Appl Radiat Isot, 2007, 65(10):1140-1151.DOI:10.1016/j.apradiso.2007.04.014.
[59] Dissoki S, Eshet R, Billauer H, et al.Modified PEG-anilinoquinazoline derivatives as potential EGFR PET agents[J].J Labelled Compd Radiopharm, 2009, 52(2):41-52.DOI:10.1002/jlcr.1569.
[60] Pantaleo MA, Mishani E, Nanni C, et al.Evaluation of modified PEG-anilinoquinazoline derivatives as potential agents for EGFR imaging in cancer by small animal PET[J].Mol Imaging Biol, 2010, 12(6):616-625.DOI:10.1007/s11307-010-0315-z.
[61] Vasdev N, Dorff PN, Gibbs AR, et al.Synthesis of 6-acrylamido-4-(2-[18F]fluoroanilino) quinazoline:a prospective irreversible EGFR binding probe[J].J Labelled Compd Radiopharm, 2005, 48(2):109-115.DOI:10.1002/jlcr.903.
[62] Vasdev N, Dorff PN, O’neil JP, et al.Metabolic stability of 6, 7-dialkoxy-4-(2-, 3-and 4-[18F]fluoroanilino) quinazolines, potential EGFR imaging probes[J].Bioorg Med Chem, 2011, 19(9):2959-2965.DOI:10.1016/j.bmc.2011.03.032.
[63] Kobus D, Giesen Y, Ullrich R, et al.A fully automated two-step synthesis of an 18F-labelled tyrosine kinase inhibitor for EGFR kinase activity imaging in tumors[J].Appl Radiat Isot, 2009, 67(11):1977-1984.DOI:10.1016/j.apradiso.2009.07.018.
[64] Wang M, Gao M, Zheng QH.The first radiosynthesis of[11C]AZD8931 as a new potential PET agent for imaging of EGFR, HER2 and HER3 signaling[J].Bioorg Med Chem Lett, 2014, 24(18):4455-4459.DOI:10.1016/j.bmcl.2014.07.092.
[65] Neto C, Fernandes C, Oliveira MC, et al.Radiohalogenated 4-anilinoquinazoline-based EGFR-TK inhibitors as potential cancer imaging agents[J].Nucl Med Biol, 2012, 39(2):247-260.DOI:10.1016/j.nucmedbio.2011.09.001.
[66] 齐传民, 李石磊, 王潇, 等.新型18F标记取代喹唑啉类化合物及其制备方法和肿瘤PET显像应用:中国, 201210036262.4[P].2013-08-21.Qi CM, Li SL, Wang X, et al.The preparation of 18F labeled quinazoline compound and its PET imaging application:CN, 201210036262.4[P].2013-08-21.
[67] 齐传民, 陈玉蓉, 冯曼, 等.新型18F标记4-氨基喹唑啉类衍生物及其制备方法和肿瘤PET显像应用:中国, 201210036250.1[P].2013-08-21.Qi CM, Chen YR, Feng M, et al.The preparation of 18F labeled 4-amino quinazoline derivatives and application of tumour PET imaging:CN, 201210036250.1[P].2013-08-21.
[68] 申宝忠.一种18F标记的喹唑啉类不可逆性EGFR正电子示踪剂及其制备方法和应用:中国, 201310711310.X[P].2014-03-26.Shen BZ.The preparation and application of 18F labeled quinazoline class irreversibility EGFR PET tracer:CN, 201310711310.X[P].2014-03-26.
[69] 申宝忠.18F标记的喹唑啉类EGFR正电子示踪剂及其制备方法和应用:中国, 201310711309.7[P].2014-03-26.Shen BZ.The preparation and application of 18F labeled quinazoline class EGFR PET tracer:CN, 201310711309.7[P].2014-03-26.
[70] 刘振峰, 董孟杰, 王国林, 等.2-氟代苯胺喹唑啉类肿瘤正电子显像剂及制备和应用:中国, 201310256474.8[P].2013-09-18.Liu ZF, Dong MJ, Wang GL, et al.The preparation and application of 2-fluoroaniline quinazoline class tumor positron imaging agent:CN, 201310256474.8[P].2013-09-18.
[71] Pisaneschi F, Nguyen QD, Shamsaei E, et al.Development of a new epidermal growth factor receptor positron emission tomography imaging agent based on the 3-cyanoquinoline core:synthesis and biological evaluation[J].Bioorg Med Chem, 2010, 18(18):6634-6645.DOI:10.1016/j.bmc.2010.08.004.
相似文献/References:
[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]杨洋,樊赛军.LXXLL模体在雌激素受体信号通路中的作用及应用价值[J].国际放射医学核医学杂志,2014,38(1):22.[doi:10.3760/cma.j.issn 1673-4114.2014.01.006]
Yang Yang,Fan Saijun.Role of LXXLL motif in modulation of estrogen receptor signaling and its potential application[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):22.[doi:10.3760/cma.j.issn 1673-4114.2014.01.006]
[3]白庆双,李宁,方佩华,等.人血清TRAb酶联免疫吸附试验检测在甲状腺疾病患者中的临床应用[J].国际放射医学核医学杂志,2014,38(2):80.[doi:10.3760/cma.j.issn.1673-4114.2014.02.003]
Bai Qingshuang,Li Ning,Fang Peihua,et al.The clinical application of human serum level of the TRAb measured by enzyme-linked immunosorbent assay in patients with thyroid diseases[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):80.[doi:10.3760/cma.j.issn.1673-4114.2014.02.003]
[4]李丽,赵长久,田国梅.CXC型趋化因子受体4及其分子显像剂在肿瘤方面的研究进展[J].国际放射医学核医学杂志,2014,38(3):190.[doi:10.3760/cma.j.issn.1673-4114.2014.03.012]
Li Li,Zhao Changjiu,Tian Guomei.Research progress of CXC chemokine receptor type 4 and molecular imaging in tumors[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):190.[doi:10.3760/cma.j.issn.1673-4114.2014.03.012]
[5]林美福,陈文新,周硕,等.18F-FES PET/CT显像在雌激素受体阳性乳腺癌诊疗中的初步应用[J].国际放射医学核医学杂志,2013,37(4):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
LIN Mei-fu,CHEN Wen-xin,ZHOU Shuo,et al.Application of 18F-FES PET/CT in diagnosis and endocrine therapy of patients with estrogen receptorpositive breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(1):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
[6]袁杰,刘兴党,韩梅.SPECT、PET神经受体和转运体显像技术在海洛因成瘾研究中的应用[J].国际放射医学核医学杂志,2013,37(1):30.[doi:10.3760/cma.j.issn.1673-4114.2013.01.009]
YUAN Jie,LIU Xing-dang,HAN Mei.Neuroreceptor and its transporters imaging by PET and SPECT in heroin addiction[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(1):30.[doi:10.3760/cma.j.issn.1673-4114.2013.01.009]
[7]鲍伟奇,邱春,管一晖.γ-氨基丁酸A型-苯二氮革受体显像剂在神经系统疾病中的应用[J].国际放射医学核医学杂志,2012,36(1):1.[doi:10.3760/cma.j.issn.1673-4114.2012.01.001]
BAO Wei-qi,QIU Chun,GUAN Yi-hui.Application of gamma-aminobutyric acid type A-benzodiazepine receptor imaging for study of neuropsychiatric disorders[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(1):1.[doi:10.3760/cma.j.issn.1673-4114.2012.01.001]
[8]程维维,王辉.促甲状腺激素受体与甲状腺癌关系的研究进展[J].国际放射医学核医学杂志,2012,36(2):69.[doi:10.3760/cma.j.issn.1673-4114.2012.02.002]
CHENG Wei-wei,WANG Hui.Progress in the relationship of thyroid-stimulating hormone receptor and thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(1):69.[doi:10.3760/cma.j.issn.1673-4114.2012.02.002]
[9]黄丽娟,陈宁,叶静,等.反义肽核酸对促甲状腺激素受体mRNA表达的影响[J].国际放射医学核医学杂志,2012,36(5):310.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.011]
HUANG Li-juan,CHEN Ning,YE Jing,et al.The effects of antisense peptide nucleic acid on the expression of thyroid stimulating hormone receptor mRNA[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(1):310.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.011]
[10]刘淼,刘兴党.生长抑素受体显像剂99Tcm-奥曲肽的SPECT研究[J].国际放射医学核医学杂志,2012,36(3):138.[doi:10.3760/cma.j.issn.1673-4114.2012.03.003]
LIU Miao,LIU Xing-dang.Development of study on SPECT imaging with radioisotope 99Tcm-octreotide[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(1):138.[doi:10.3760/cma.j.issn.1673-4114.2012.03.003]
[11]邢宇,赵新明.放射性核素标记HER2亲和体分子探针精准诊疗的研究进展[J].国际放射医学核医学杂志,2016,40(2):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
Xing Yu,Zhao Xinming.Advances in radionuclide-labeled HER2 affibody molecular probes for precise diagnosis and treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
[12]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[13]周晓靓,王浩,施培基,等.表皮生长因子受体-酪氨酸激酶肿瘤分子显像剂的研究进展[J].国际放射医学核医学杂志,2013,37(2):100.[doi:10.3760/cma.j.issn.1673-4114.2013.02.010]
ZHOU Xiao-liang,WANG Hao,SHI Pei-ji,et al.The developme nt of epidermal growth factor receptor molecular imaging in cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(1):100.[doi:10.3760/cma.j.issn.1673-4114.2013.02.010]
[14]柳杰,刘佩芳.乳腺癌X射线征象与雌激素受体、孕激素受体和C-erbB-2表达相关性的研究进展[J].国际放射医学核医学杂志,2012,36(5):301.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.009]
LIU Jie LIU,Pei-fang.Development of the correlation study between mammographic appearances and expression of estrogen receptor, progesterone receptor and C-erbB-2 in patients with breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(1):301.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.009]
[15]王相成,王雪梅,何玉林,等.PET-CT表皮生长因子受体显像的研究进展[J].国际放射医学核医学杂志,2010,34(5):266.[doi:10.3760/cma.j.issn.1673-4114.2010.05.003]
WANG Xiang-cheng,WANG Xue-mei,HE Yu-lin,et al.Study progress of PET-CT epidermal growth factor receptor imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(1):266.[doi:10.3760/cma.j.issn.1673-4114.2010.05.003]
[16]汪永红,陈文新,何品玉.肿瘤表皮生长因子受体的分子显像研究[J].国际放射医学核医学杂志,2009,33(4):204.[doi:10.3760/cma.j.issn.1673-4114.2009.04.004]
WANG Yong-hong,CHEN Wen-xin,HE Pin-yu.Tumor epidermal growth factor receptor molecular imaging research[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(1):204.[doi:10.3760/cma.j.issn.1673-4114.2009.04.004]
[17]郑玉民,王自正,王峰,等.以表皮生长因子受体为靶点的肿瘤分子靶向治疗[J].国际放射医学核医学杂志,2007,31(1):21.
ZHENG Yu-min,WANG Zi-zheng,WANG Feng,et al.Epidermal growth factor receptor targeted molecularly therapies of cancers[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(1):21.
[18]袁卫红,罗志航,彭荣宗,等.肺癌与表皮生长因子及其受体关系的研究[J].国际放射医学核医学杂志,2006,30(5):261.
YUAN Wei-hong,LUO Zhi-hang,PENG Rong-zong,et al.The study on the correlation between EGF, EGFR and lung carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(1):261.
[19]何蕊,朱高红.甲状腺髓样癌靶向治疗的研究进展[J].国际放射医学核医学杂志,2018,(2):154.[doi:10.3760/cma.j.issn.1673-4114.2018.02.010]
He Rui,Zhu Gaohong.Research status of medullary thyroid carcinoma targeted therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(1):154.[doi:10.3760/cma.j.issn.1673-4114.2018.02.010]